Patent ID: 7226755

Claim:
A method for identifying an agent useful for treating an angiogenesis mediated disorder, comprising: a) exposing an agent to Human Protein Tyrosine Phosphatase—beta (HPTPbeta) and Vascular Endothelial Growth Factor Receptor—Type 2 (VEGFR2); b) determining whether the agent modulates HPTPbeta activity and VEGFR2 activity, and c) identifying those agents that modulate HPTPbeta activity and VEGFR2 activity as useful for treating an angiogenesis mediated disorder; wherein the angiogenesis mediate disorder is selected from: (i) disorders, diseases, and/or unwanted conditions characterized by unwanted or elevated angiogenesis selected from the group consisting of diabetic retinopathy, macular degeneration, sickle cell anemia, syphilis, pseudoxanthoma elasticum, Paget's disease, vein or artery occlusion, carotid obstructive disease, chronic uveitus, chronic vitritis, mycobacterial infections, Lyme's disease, systemic lupus erythematosis, retinopathy of prematurity, Eales' disease, Behcet's disease, presumed ocular histoplasmosis, Best's disease, myopia, optic pits, Stargardt's disease, pars planitis, chronic retinal detachment, hyperviscosity syndromes, toxoplasmosis, proliferative vitroeretinopathy, Crohn's disease, ulcerative colitis, psoriasis, sarcoidosis, rheumatoid arthritis, hemangiomas, Osler-Weber-Rendu disease, hereditary hemorrahic telangiectasia, solid tumors, blood borne tumors, and acquired immune deficiency syndrome; or (ii) disorders, diseases, and/or unwanted conditions characterized by wanted or reduced angiogenesis selected from the group consisting of skeletal muscle ischemia, myocardial ischemia, stroke, coronary artery disease, peripheral vascular disease, and tissue repair where tissue has been damaged by trauma, surgical procedures, irradiation, laceration, toxic chemicals, viral infection, bacterial infection, non-healing wounds, or burns, or where tissue has been damaged by arthritis or osteoporosis; wherein the amino acid sequence of HPTPbeta is at least 95% homologous to the amino acid sequence of SEQ ID NO: 2, 9, 15, or 16; and wherein the amino acid sequence of VEGFR2 is at least 95% homologous to the amino acid sequence of SEQ ID NO: 6 or 11.